Rhythm Pharmaceuticals Financial Statements
NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 90.78 0.00%
Rhythm Pharmaceuticals revenue and earnings
In fiscal 2025, Rhythm Pharmaceuticals generated $189.8 million in revenue, up 45.8% from fiscal 2024, its 5th consecutive year of revenue growth. Rhythm Pharmaceuticals reported a net loss of $196.5 million, compared with a loss of $260.6 million a year earlier. Gross margin was 89.7% (flat year over year) and operating margin -101.2%.
Diluted earnings per share came in at -$3.11.
Summary generated from market data by MetaCap's automated system. Methodology
Rhythm Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 189.76M | 130.13M | 77.43M | 23.64M | 3.15M | 0 | 0 | 0 | 0 | 0 |
| Revenue growth (YoY) | +45.83% | +68.06% | +227.56% | +649.46% | — | — | — | — | — | — |
| Cost of Revenue | 19.49M | 13.37M | 9.30M | 2.13M | 599.00K | — | — | — | — | — |
| Gross Profit | 170.26M | 116.76M | 68.13M | 21.50M | 2.56M | — | — | — | — | — |
| Operating Expenses | 362.28M | 382.26M | 252.48M | 200.66M | 172.61M | 136.57M | 146.00M | 78.42M | 32.41M | 25.91M |
| Research & Development | 167.34M | 237.96M | 134.95M | 108.63M | 104.13M | 90.45M | 109.45M | 50.34M | 22.89M | 19.59M |
| Selling, General & Admin | 194.94M | 144.30M | 117.53M | 92.03M | 68.49M | 46.13M | 36.55M | 28.08M | 9.52M | 6.31M |
| Operating Income | -192.02M | -265.50M | -184.36M | -179.16M | -170.06M | -136.57M | -146.00M | -78.42M | -32.41M | -25.91M |
| Interest Expense | 20.58M | 20.60M | 13.89M | 5.20M | — | — | — | — | — | — |
| Other Income (Expense) | -4.03M | 5.25M | 243.00K | -1.96M | 100.45M | 2.58M | 5.27M | 4.35M | -1.30M | 33.00K |
| Pretax Income | -196.04M | -260.26M | -184.11M | -181.12M | -69.61M | — | — | — | — | — |
| Income Tax | 497.00K | 346.00K | 564.00K | — | — | — | — | — | — | — |
| Net Income | -196.54M | -260.60M | -184.68M | -181.12M | -69.61M | -134.00M | -140.73M | -74.06M | -33.71M | -25.87M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 | -3.04 | -3.86 | -2.39 | -2.83 | -2.85 |
| EPS (Diluted) | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 | -3.04 | -3.86 | -2.39 | -2.83 | -2.85 |
| Shares Outstanding (Basic) | 64.98M | 61.00M | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 10.20M |
| Shares Outstanding (Diluted) | 64.98M | 61.00M | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 10.20M |
| EBITDA | -191.52M | -264.80M | -183.46M | -178.26M | -169.24M | -135.88M | -145.17M | -77.97M | -32.19M | -25.76M |
| Gross Margin | 89.73% | 89.73% | 87.99% | 90.98% | 81.01% | — | — | — | — | — |
| Operating Margin | -101.19% | -204.04% | -238.10% | -757.92% | -5391.85% | — | — | — | — | — |
| Net Margin | -103.57% | -200.27% | -238.52% | -766.22% | -2207.10% | — | — | — | — | — |
This table shows 10 annual periods of Rhythm Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RYTM's reporting calendar. What is a income statement?